Estrella Immunopharma annual cash and equivalents
2021
2022
2022
2023
2024
2024
2025
Estrella Immunopharma Cash & Equivalents Growth & History (ESLA)
Estrella Immunopharma's cash and equivalents was $1.4M for fiscal 2025.
View full Estrella Immunopharma company overviewEstrella Immunopharma annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.4M | $467,386 | +50.97% |
| 2024 · Dec 31 | 2024-12-31 | $916,916 | — | — |
| 2024 · Jun 30 | 2024-06-30 | $4.2M | $1.7M | +68.02% |
| 2023 | 2023-06-30 | $2.5M | −$1.6M | −39.36% |
| 2022 | 2022-12-31 | $40,802 | −$438,066 | −91.48% |
| 2022 | 2022-06-30 | $4.1M | — | — |
| 2021 | 2021-12-31 | $478,868 | — | — |
Estrella Immunopharma quarterly cash and equivalents
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $100,000 | −$1.2M | −92.40% |
| Q1 2026 | 2026-03-31 | $1.9M | $1.5M | +357.30% |
| Q4 2025 | 2025-12-31 | $1.4M | $467,386 | +50.97% |
| Q3 2025 | 2025-09-30 | $1.6M | −$170,893 | −9.51% |
| Q2 2025 | 2025-06-30 | $1.3M | −$2.8M | −68.39% |
| Q1 2025 · Mar 31 | 2025-03-31 | $421,473 | −$4.3M | −91.08% |
| Q4 2024 · Dec 31 | 2024-12-31 | $916,916 | −$8.1M | −89.86% |
| Q1 2025 · Sep 30 | 2024-09-30 | $1.8M | −$20.3M | −91.88% |
| Q4 2024 · Jun 30 | 2024-06-30 | $4.2M | $1.7M | +68.02% |
| Q3 2024 | 2024-03-31 | $4.7M | — | — |
| Q2 2024 | 2023-12-31 | $9.0M | $9.0M | +22070.52% |
| Q1 2024 | 2023-09-30 | $22.1M | $22.1M | +29916.81% |
| Q4 2023 | 2023-06-30 | $2.5M | $2.4M | +2708.24% |
| Q4 2022 | 2022-12-31 | $40,802 | −$438,066 | −91.48% |
| Q3 2022 | 2022-09-30 | $73,752 | −$247,972 | −77.08% |
| Q2 2022 | 2022-06-30 | $88,281 | — | — |
| Q1 2022 | 2022-03-31 | $321,724 | — | — |
| Q4 2021 | 2021-12-31 | $478,868 | — | — |
| Q3 2021 | 2021-09-30 | $321,724 | — | — |
Estrella Immunopharma cash and equivalents trends
Between the periods ended 2021-12-31 and 2025-12-31, Estrella Immunopharma's cash and equivalents increased from $478,868 to $1.4M, a change of $905,434. The latest reported quarter, Q2 2026, shows $100,000.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Estrella Immunopharma source filings ↗